-- The latest market report published by Credence Research, Inc. "Global Lambert-Eaton Myasthenic Syndrome Market–Growth, Future Prospects, Competitive Analysis, 2019-2027," the global market for Lambert-Eaton Myasthenic Syndrome is expected to expand at a CAGR of 6.7 percent from 2019 to 2027.
The global prevalence rate of Lambert-Eaton Myasthenic Syndrome (LEMS) is around 2.8 per million people, according to statistics provided by the National Organization for Rare Diseases (NORD). In cases where LEMS is associated with small cell lung cancer (SCLC), it occurs more in the male population compared to female in older patients. Healthcare agencies around the globe are stipulating effective screening and treatment guidelines for the treatment of LEMS.
There is no permanent cure for LEMS treatment in pediatric patients. The drugs currently prescribed by physicians around the world are intended to attenuate the clinical manifestations of LEMS in the adult population. Potassium channel blocker, cholinesterase inhibitor, immune therapy, intravenous immunoglobulin and plasmapheresis etc. are used for adult population LEMS treatment. The recent approval and designation of orphan drugs by the USFDA and the fast track status achieved by amifampridine will be widely used to treat LEMS in children aged 6 to 17 years.
Browse the full report Lambert-Eaton Myasthenic Syndrome Market - Growth, Future Prospects, Competitive Analysis, 2019 – 2027 report at https://www.credenceresearch.com/report/lambert-eaton-myasthenic-syndrome-market
North America has a 39 percent share of the regional Lambert-Eaton Myasthenic Syndrome market. The primary factors responsible for its global dominance are significant increases in clinical research activities to cure rare autoimmune disorders such as LEMS. According to the National Organization for Rare Diseases (NORD) research findings, there are approximately 400 known cases of LEMs in the United States. The domicile of key players such as Biomarin Pharmaceutical, Inc., Catalyst Pharmaceuticals, Inc., Merck & Co., Inc., etc., will further boost market growth in the North American region. Europe holds a market share of 34.5 percent due to the high incidence rate of LEMS in the European community. Asia Pacific has a 14 percent share due to the huge population base suffering from small cell lung cancer (SCLC), 40 percent of which show remarkable clinical manifestation of LEMS. Proactive government initiatives by providing huge financial support to combat orphan diseases.
Pharmaceutical manufacturers providing medications for the treatment of Lambert-Eaton Myasthenic Syndrome are Allergan, Plc., Biomarin Pharmaceutical, Inc., Catalyst Pharmaceuticals, Inc., F. Hoffman-La Roche Ltd., GlaxoSmithkline, Plc., Jacobus Pharmaceutical Company, Inc., Kawasumi Laboratories, Inc., Merck & Co., Inc., Mitsubishi Pharma Corporation.
Key Market Movements:
The increasing incidence rate of LEMS in children aged between 6 to 17 years of age.
Recent USFDA approval and designation of orphan drugs and fast track status for the development and sale of amifampridine for treating LEMS in children.
The supportive regulatory environment provided by healthcare agencies worldwide for the treatment of rare autoimmune diseases.
Request For Sample: https://www.credenceresearch.com/sample-request/59722
ToC:
Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Treatment
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation
Chapter 2. Executive Summary
..............
Chapter 3. Lambert-Eaton Myasthenic Syndrome Market: Dynamics and Future Outlook
.............
Chapter 4. Global Lambert-Eaton Myasthenic Syndrome Market, by Treatment
4.1. Overview
4.2. Potassium Channel Blockers (Amifampridine)
4.3. Cholinesterase Inhibitor (Pyridostigmine)
4.4. Immune Therapy
4.5. Intravenous Immunoglobulin
4.6. Plasmapheresis
Chapter 5. Global Lambert-Eaton Myasthenic Syndrome Market, by Geography
.............
Chapter 6. Company Profiles
6.1. Allergan, Plc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Biomarin Pharmaceutical, Inc.
6.3. Catalyst Pharmaceuticals, Inc.
6.4. F. Hoffman-La Roche Ltd.
6.5. GlaxoSmithkline, Plc.
6.6. Jacobus Pharmaceutical Company, Inc.
6.7. Kawasumi Laboratories, Inc.
6.8. Merck & Co., Inc.
6.9. Mitsubishi Pharma Corporation
6.10. Novartis AG
............................toc continued
Browse the full report Lambert-Eaton Myasthenic Syndrome Market - Growth, Future Prospects, Competitive Analysis, 2019 – 2027 report at https://www.credenceresearch.com/report/lambert-eaton-myasthenic-syndrome-market
About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.
MenaFN: Lambert-Eaton Myasthenic Syndrome Market Size and Opportunities: expanding at a CAGR of 6.7% from 2019 to 2027
Contact Info:
Name: Chris Smith
Email: Send Email
Organization: Credence Research
Address: 105 N 1st ST #429, SAN JOSE,, CA 95103, United States
Phone: 18003618290
Website: https://www.credenceresearch.com
Release ID: 526766
Google
RSS